IL1B and neoplasm: Differential gene expression and pathway enrichment analysis revealed that regorafenib treatment broadly suppressed several pathways related to cancer cell proliferation, motility, and invasion, as well as angiogenesis, fibrosis, and tumor-promoting immune processes, including IL-1β activity and myeloid cell accumulation (Fig. 7C).